Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight...
Zapisane w:
Główni autorzy: | , , , , , , , , , , , , , , , |
---|---|
Format: | Książka |
Wydane: |
Medical Journals Sweden,
2024-11-01T00:00:00Z.
|
Hasła przedmiotowe: | |
Dostęp online: | Connect to this object online. |
Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
Internet
Connect to this object online.3rd Floor Main Library
Sygnatura: |
A1234.567 |
---|---|
Egzemplarz 1 | Dostępne |